Total Funding
87
70
Total FundingEquity Crowdfunding raised
Growth Score 87 in past quarter
-4 pts
Heat Score 70 in past quarter
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
31237
Opticyte is transforming care for the leading causes of organ failure, including sepsis, with real-time measurements.
- Kenneth Schenkman: Cofounder & CMO
- Lori Arakaki: CoFounder & CEO
About the Company
Opticyte, Inc, a medical device innovator developing proprietary advanced algorithms and tailored optical spectroscopy technology to measure and detect low oxygen levels in cells to prevent organ failure. Opticyte is developing the first Cell O2 Monitor for reducing organ failure. Founded in 2016, Opticyte, Inc, is a spinoff from the University of
Washington. Headquartered in Seattle, WA, Opticyte employs engineering, regulatory, and communications teams with deep experience in bringing medical devices to market.
Women Founded
Women Led
